-
1
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
-
2
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
-
3
-
-
77953930730
-
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
-
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
-
(2010)
N Engl J Med
, vol.362
, pp. 2380-2388
-
-
Maemondo, M.1
Inoue, A.2
Kobayashi, K.3
Sugawara, S.4
Oizumi, S.5
Isobe, H.6
-
4
-
-
35548962203
-
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
-
Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98:1817-24.
-
(2007)
Cancer Sci
, vol.98
, pp. 1817-1824
-
-
Mitsudomi, T.1
Yatabe, Y.2
-
5
-
-
13844317894
-
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
-
Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
-
(2005)
N Engl J Med
, vol.352
, pp. 786-792
-
-
Kobayashi, S.1
Boggon, T.J.2
Dayaram, T.3
Janne, P.A.4
Kocher, O.5
Meyerson, M.6
-
6
-
-
18244371651
-
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
-
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
-
(2005)
PLoS Med
, vol.2
, pp. e73
-
-
Pao, W.1
Miller, V.A.2
Politi, K.A.3
Riely, G.J.4
Somwar, R.5
Zakowski, M.F.6
-
7
-
-
84921032852
-
Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: A meta-analysis
-
Qiu M, Wang J, Xu Y, Ding X, Li M, Jiang F, et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2015;24:206-12.
-
(2015)
Cancer Epidemiol Biomarkers Prev
, vol.24
, pp. 206-212
-
-
Qiu, M.1
Wang, J.2
Xu, Y.3
Ding, X.4
Li, M.5
Jiang, F.6
-
8
-
-
66849091226
-
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer
-
Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009;27:2653-9.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2653-2659
-
-
Bai, H.1
Mao, L.2
Wang, H.S.3
Zhao, J.4
Yang, L.5
An, T.T.6
-
9
-
-
79957767374
-
Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors
-
Brevet M, Johnson ML, Azzoli CG, Ladanyi M. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 2011;73:96-102.
-
(2011)
Lung Cancer
, vol.73
, pp. 96-102
-
-
Brevet, M.1
Johnson, M.L.2
Azzoli, C.G.3
Ladanyi, M.4
-
10
-
-
34548593298
-
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
-
Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 2007;97:778-84.
-
(2007)
Br J Cancer
, vol.97
, pp. 778-784
-
-
Kimura, H.1
Suminoe, M.2
Kasahara, K.3
Sone, T.4
Araya, T.5
Tamori, S.6
-
11
-
-
81855208762
-
Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas
-
Taniguchi K, Uchida J, Nishino K, Kumagai T, Okuyama T, Okami J, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011;17:7808-15.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 7808-7815
-
-
Taniguchi, K.1
Uchida, J.2
Nishino, K.3
Kumagai, T.4
Okuyama, T.5
Okami, J.6
-
13
-
-
84896737232
-
Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data
-
Kukita Y, Uchida J, Oba S, Nishino K, Kumagai T, Taniguchi K, et al. Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. PLoS One 2013;8:e81468.
-
(2013)
PLoS One
, vol.8
-
-
Kukita, Y.1
Uchida, J.2
Oba, S.3
Nishino, K.4
Kumagai, T.5
Taniguchi, K.6
-
14
-
-
79960597679
-
An integrated semiconductor device enabling non-optical genome sequencing
-
Rothberg JM, Hinz W, Rearick TM, Schultz J, Mileski W, Davey M, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature 2011;475:348-52.
-
(2011)
Nature
, vol.475
, pp. 348-352
-
-
Rothberg, J.M.1
Hinz, W.2
Rearick, T.M.3
Schultz, J.4
Mileski, W.5
Davey, M.6
-
15
-
-
23844465454
-
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp
-
Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65:7276-82.
-
(2005)
Cancer Res
, vol.65
, pp. 7276-7282
-
-
Nagai, Y.1
Miyazawa, H.2
Huqun3
Tanaka, T.4
Udagawa, K.5
Kato, M.6
-
16
-
-
0032377357
-
Approximate is better than 'exact' for interval estimation of binomial proportions
-
Agresti A, Coull BA. Approximate is better than 'exact' for interval estimation of binomial proportions. American Statistician 1998;52:119-26.
-
(1998)
American Statistician
, vol.52
, pp. 119-126
-
-
Agresti, A.1
Coull, B.A.2
-
17
-
-
33748074447
-
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer
-
Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006;66:7854-8.
-
(2006)
Cancer Res
, vol.66
, pp. 7854-7858
-
-
Inukai, M.1
Toyooka, S.2
Ito, S.3
Asano, H.4
Ichihara, S.5
Soh, J.6
-
18
-
-
84896371874
-
Detection of circulating tumor DNA in early- and late-stage human malignancies
-
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
-
(2014)
Sci Transl Med
, vol.6
-
-
Bettegowda, C.1
Sausen, M.2
Leary, R.J.3
Kinde, I.4
Wang, Y.5
Agrawal, N.6
-
19
-
-
84864045330
-
EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas
-
Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 2012;17:978-85.
-
(2012)
Oncologist
, vol.17
, pp. 978-985
-
-
Chen, Z.Y.1
Zhong, W.Z.2
Zhang, X.C.3
Su, J.4
Yang, X.N.5
Chen, Z.H.6
-
20
-
-
84887497121
-
The quest to overcome resistance to EGFR-targeted therapies in cancer
-
Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013;19:1389-400.
-
(2013)
Nat Med
, vol.19
, pp. 1389-1400
-
-
Chong, C.R.1
Janne, P.A.2
-
21
-
-
84875520648
-
Analysis of circulating tumor DNA to monitor metastatic breast cancer
-
Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
-
(2013)
N Engl J Med
, vol.368
, pp. 1199-1209
-
-
Dawson, S.J.1
Tsui, D.W.2
Murtaza, M.3
Biggs, H.4
Rueda, O.M.5
Chin, S.F.6
-
22
-
-
84863000299
-
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
-
Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, BerlinJ, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
-
(2012)
Nature
, vol.486
, pp. 537-540
-
-
Diaz, L.A.1
Williams, R.T.2
Wu, J.3
Kinde, I.4
Hecht, J.R.5
Berlin, J.6
-
23
-
-
84906250256
-
Gefitinib treatment in EGFR mutated Caucasian NSCLC: Circulating-free tumor DNA as a surrogate for determination of EGFR status
-
Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345-53.
-
(2014)
J Thorac Oncol
, vol.9
, pp. 1345-1353
-
-
Douillard, J.Y.1
Ostoros, G.2
Cobo, M.3
Ciuleanu, T.4
Cole, R.5
McWalter, G.6
|